Cancer drug T-DXd safety tracked in ongoing rollover study

NCT ID NCT06174987

Recruiting now Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study offers continued access to the cancer drug T-DXd for up to 50 people with advanced or metastatic cancer who are already benefiting from it in earlier trials. Researchers will monitor long-term safety, including serious side effects and reasons for stopping or reducing the drug. The goal is to ensure the treatment remains safe over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: T-DXd (trastuzumab deruxtecan)
What this could lead to: If successful, this study could confirm that long-term use of T-DXd is safe for people with advanced cancer, supporting its continued use as a treatment option.
What could go wrong: This is a small, open-label rollover study (50 participants) focused on safety, not on proving effectiveness. It may not detect rare side effects or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER METASTATIC CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

A.C. Camargo Cancer Center
NOT_YET_RECRUITING

São Paulo, Brazil
Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Complejo Hospitalario Universitario A Coruña
RECRUITING

A Coruña, 15006, Spain
Duke University - Trent Center
RECRUITING

Durham, North Carolina, 27710, United States
Flinders Medical Center
ACTIVE_NOT_RECRUITING

Bedford Park, 5042, Australia
Grand Hôpital de Charleroi
RECRUITING

Charleroi, 6000, Belgium
Hospital Ruber Internacional
WITHDRAWN

Madrid, 28034, Spain
Hospital Universitari Dexeus
NOT_YET_RECRUITING

Distrito de Les Corts, 08028, Spain
Hospital Universitari Vall d'Hebron
RECRUITING

Barcelona, 08035, Spain
IBCC Nucleo de Pequisa e Ensino
NOT_YET_RECRUITING

São Paulo, Brazil
ICO l'Hospitalet - Hospital Duran i Reynals
RECRUITING

L'Hospitalet de Llobregat, 08908, Spain
Institut Gustave Roussy
RECRUITING

Villejuif, 94805, France
Instituto Aericas
NOT_YET_RECRUITING

Rio de Janeiro, Brazil
Istituto Nazionale Tumori Fondazione G. Pascale
WITHDRAWN

Naples, 80131, Italy
Kyungpook National University Chilgok Hospital
RECRUITING

Daegu, 41404, South Korea
Miami Cancer Institute
RECRUITING

Miami, Florida, 33176, United States
Monash Medical Center
WITHDRAWN

Melbourne, 3168, Australia
National Cancer Center
RECRUITING

Gyeonggi-do, 10408, South Korea
National Cancer Center Hospital
RECRUITING

Chūō, 104-0045, Japan
National Cheng Kung University Hospital
WITHDRAWN

Tainan, 704, Taiwan
National Taiwan University Hospital
WITHDRAWN

Taipei, 10002, Taiwan
Ospedale San Raffaele
RECRUITING

Milan, 20132, Italy
Rabin Medical Center
ACTIVE_NOT_RECRUITING

Petah Tikva, Israel
Royal Surrey County Hospital
WITHDRAWN

Guildford, GU2 7XX, United Kingdom
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Seoul National University Bundang Hospital
WITHDRAWN

Gyeonggi-do, 13620, South Korea
Seoul National University Hospital
RECRUITING

Jongno-gu, 03080, South Korea
Severance Hospital, Yonsei University
RECRUITING

Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.